Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

Farzin Sohraby; Hassan Aryapour

doi:10.1371/journal.pone.0251910

. 2021 May 19;16(5):e0251910. doi: 10.1371/journal.pone.0251910

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

Farzin Sohraby ^1,^#, Hassan Aryapour ^1,^*,^#

Editor: Emilio Gallicchio²

PMCID: PMC8133426 PMID: 34010326

Abstract

The COVID-19 disease has infected and killed countless people all over the world since its emergence at the end of 2019. No specific therapy for COVID-19 is not currently available, and urgent treatment solutions are needed. Recent studies have found several potential molecular targets, and one of the most critical proteins of the SARS-CoV-2 virus work machine is the Papain-like protease (Plpro). Potential inhibitors are available, and their X-ray crystallographic structures in complex with this enzyme have been determined recently. However, their activities against this enzyme are insufficient and need to be characterized and improved to be of clinical values. Therefore, in this work, by utilizing the Supervised Molecular Dynamics (SuMD) simulation method, we achieved multiple unbinding events of Plpro inhibitors, GRL0617, and its derivates, and captured and understood the details of the unbinding pathway. We found that residues of the BL2 loop, such as Tyr268 and Gln269, play major roles in the unbinding pathways, but the most important contributing factor is the natural movements and behavior of the BL2 loop, which can control the entire process. We believe that the details found in this study can be used to refine and optimize potential inhibitors like GRL0617 and design more efficacious inhibitors as a treatment for the SARS-CoV-2 virus.

Introduction

The emergence of a global pandemic known as the Covid-19 disease caused by the SARS-CoV-2 virus has created close to 45 million infected and 1.2 million deaths until the end of October 2020. This catastrophic event caused unmeasurable damage to both human lives and the global economy [1, 2]. The lack of sufficient treatments has led to an ever-increasing number of deaths, and options are urgently needed [3–6]. Researchers worldwide are working as hard as possible to develop treatment solutions, and since the beginning of the pandemic, several options have been proposed [7–12]. Repurposing existing antivirals such as Remdesivir and Favipiravir have shown antiviral activity against SARS-CoV-2 in clinical trials [8, 13–16]. However, these drugs can only be used for emergencies, and their efficacy is not sufficient. Therefore, more selective and more effective treatments are needed to stop and cut the chains of the infected people. Recent studies have shown that one of the most critical proteins of the SARS-CoV-2 virus work machine is the Papain-like protease (Plpro). This cysteine protease can cleave the viral polyproteins (pp1a and pp1ab) into mature functional proteins [17, 18].

Moreover, this enzyme is also responsible for recognizing the Ubiquitin (Ub) and the Ub-like (Ubl) modifier interferon-stimulated gene 15 (ISG15), reversing their mechanism and make the virus escape the immune response of the host cell [19–22]. These make the Plpro an attractive target protein for arresting the virus activity and overcoming this disease. However, firstly, selective and effective inhibitors must be designed.

In the last 15 years since the emergence of SARS-CoV, selective inhibitors of the Plpro of SARS-CoV have been identified with very high inhibitory activities, but they were never considered for further investigations or human use as the virus disappeared. However, The Plpro enzyme of SARS-CoV and the SARS-CoV-2 are very similar in structure and sequence (83% identity) [23]. Therefore, there was always this strong probability that the identified inhibitors of SARS-CoV Plpro can be used against the SARS-CoV-2 Plpro. One of the most potent inhibitors identified originally for the inhibition of SARS-CoV Plpro was GRL0617. In 2008, Ratia et al. introduced naphthalene-based SARS-CoV Plpro inhibitors such as GRL0617 with an IC₅₀ value of 0.6 μM [24]. Recently, Osipiuk et al. synthesized derivates of GRL0617 and tested them against the SARS-CoV-2 Plpro, and introduced potent inhibitors [23]. Apart from the GRL0617 (IC₅₀ = 2.3 μM), the synthesized compounds had an IC₅₀ range of 5.1 to 32.8 μM, which show their great potency.

Furthermore, the 3D crystallographic structure determination of the protein-ligand complexes is a remarkable finding and can immensely accelerate Structure-Based Drug Design (SBDD) investigations for identifying highly selective and highly effective entities to fight the SARS-CoV-2 virus. Although several covalent inhibitors containing aldehyde and Michael acceptor have been identified, they have not sufficient bioavailability and failed in clinical trials [25]. Their undesirable reaction with thiol groups renders them highly toxic despite good activity against cysteine proteases such as Plpro. Therefore, safe, reversible non-covalent small molecule inhibitors are preferred.

Computational Methods in SBDD such as Unbiased Molecular Dynamics (UMD) simulation can accurately investigate the important details of mechanisms such as binding and unbinding mechanisms that are vital for rational drug design [26–32]. Utilizing these fast and accurate methods is of great importance when urgent treatment solutions are needed.

In this work, by utilizing a specialized UMD approach, the supervised MD method, non-covalent inhibitors of SARS-CoV-2 Plpro with available 3D structures were taken into account, and their unbinding pathways were revealed. The main goal of this investigation was extracting the key details governing the efficacy of these inhibitors to gain and report the necessary and valuable information needed for designing more selective and more effective drug candidates of clinical value.

Method

There are only four unique protein-ligand complexes of Plpro in complex with inhibitor available in Protein Data Bank [33], Plpro in complex with GRL0617 (PDB ID: 7CMD) [34], PLP_Snyder441 (PDB ID: 7JN2) [23], PLP_Snyder495 (PDB ID: 7JIT) [23] and PLP_Snyder530 (PDB ID: 7JIW) [23]. The 3D crystallographic structures were obtained and then cleaned and prepared by UCSF Chimera software [35]. All of the unnecessary molecules, such as water molecules, were deleted from the structures, and the protein-ligand complexes’ structures were ready for the next step, the MD simulations. All of the MD simulations were done by GROMACS 2018 package [36] and OPLS-AA force field [37]. The 3D structures of the co-crystallized inhibitors were parameterized using ACEPYPE [38] with the default setting for assigning the partial charges and atom types. For the construction of the simulation systems, first, the related protein-ligand complex was placed in the center of a triclinic box with a distance of 1 nm from all edges and then solvated with TIP3P water model [39]. Then, sodium and chloride ions were added to produce a neutral physiological salt concentration of 150 mM. Each system was energy minimized, using the steepest descent algorithm, until the Fmax was less than 10 kJ.mol^-1.nm^-1. All of the covalent bonds were constrained using the Linear Constraint Solver (LINCS) algorithm [40] to maintain constant bond lengths. The long-range electrostatic interactions were treated using the Particle Mesh Ewald (PME) method [41], and the cut-off radii for Coulomb and Van der Waals short-range interactions were set to 0.9 nm for the interaction of the protein-ligand complex. The modified Berendsen (V-rescale) thermostat [42] and Parrinello–Rahman barostat [43] respectively were applied for 100 and 300 ps to keep the system in the stable environmental conditions (310 K, 1 Bar). Finally, SuMD simulations were carried out under the periodic boundary conditions (PBC), set at XYZ coordinates to ensure that the atoms had stayed inside the simulation box, and the subsequent analyses were then performed using GROMACS utilities, VMD [44] and USCF Chimera, and also the plots were created using Daniel’s XL Toolbox (v 7.3.2) add-in [45]. The free energy landscapes were rendered using Matplotlib [46]. In addition, to estimate the binding free energy we used the g_mmpbsa package [47]. The results of the MMPBSA method for each replica and each protein-inhibitor complex is represented as protein-ligand interaction energies. The contribution of each residue during the simulations was calculated by the sum of VdW and electrostatic interaction energies between important residues and the inhibitors during the unbinding pathway. The data was extracted from the trajectory and energy files of simulation using Gromacs’s modules such as “gmx rerun” and “gmx energy”.

The SuMD simulations were divided into a series of short simulations, called replicas, with a duration time of only 500 ps. The starting point of every series is the crystallographic conformation of the co-crystallized inhibitor in the binding pocket. Then, two points are defined, one was the Center of Mass (COM) of the inhibitor, and the other was set to be the COM of two residues in the deep parts of the binding pocket, Y258 and T259. The distance between these two points was checked at the end of each short 500 ps run. The frame with the highest distance was then selected as the starting point of the next 500 ps simulation. This procedure was repeated until the distance values went above 4 nm, which is a direct sign of the unbinding event.

Results & discussion

SuMD simulation of the unbinding pathways

For each of the four inhibitors, three series of SuMD simulations were performed, and all of them were successful, and unbinding events were achieved in the nanosecond time-scale (Table 1). In terms of duration times of the unbinding pathways, the more potent GRL0617 showed better performance than the others and spent more time in the binding pocket, except for the PLP_Snyder530 and the already published activity assays also suggest the same. However, comparing the duration times of the unbinding events may not be a correct way to compare the potency of the inhibitors.

Table 1. The duration times of the unbinding pathways of the inhibitors (ns) with respect to their activity.

Inhibitors	Replica series No 1	Replica series No 2	Replica series No 3	experimental activity (μM) [23]
GRL0617	121	72	94	2.3
PLP_Snyder441	166.5	75.5	31	NA
PLP_Snyder495	16	24	40	5.1
PLP_Snyder530	152.5	77.5	57.5	6.4

Open in a new tab

The Plpro has four major domains, the N-terminal ubiquitin-binding domain, the α-helical thumb domain, the β-stranded finger domain, and the palm domain (Fig 1). The Catalytic active site is located in the palm domain where the catalytic triad, Cys111, His272, and Asp286 are placed [34, 48]. The binding site of the GRL0617 and its derivates is also in the palm domain. However, they do not interact with the catalytic triad and only occupy a fraction of the catalytic active site. There is an essential loop called the BL2 loop in the palm domain, which recognizes the substrate. This loop makes room for substrate and keeps it stable during the cleaving reaction [23, 34, 49–51]. The known inhibitors of SARS-CoV-2 Plpro mainly interact with this loop as this loop can construct a binding site by folding and contracting towards the center of the enzyme. In the crystallographic conformations of the inhibitors, there are stable interactions between the ligands and the residues of the binding site. Important residues such as Tyr 264, Tyr268, and Gln269 on the tip of the BL2 loop can make Pi-stacking and hydrogen bonds, respectively, with this set of inhibitors. By inspecting the results, we found that Gln269 makes these inhibitors more stable in the binding pocket, whereas Tyr268 can control them. GRL0617 and its derivates are naphthalene-based compounds, and their aromatic interaction with Tyr268 is a contributing factor of their unbinding process, which will be discussed later. In the next section, the details achieved from the unbinding pathways of each inhibitor are explained.

Fig 1 — The superimposed crystallographic structures of the apo form (PDB ID: 6W9C), colored in green, and the complexed form of SARS-CoV-2 Plpro in complex with GRL0617 (PDB ID: 7CMD) [34] colored in yellow. The sequence from Thr266 to Gly272 is considered as the BL2 loop.

In the GRL0617-Plpro complex, GRL0617 showed to be one of the most stable inhibitors. In all three series of replicas performed, two stable hydrogen bonds with the Gln269 were observed, one with the nitrogen atom of the backbone and one with the nitrogen atom of the side chain of Gln269 (Fig 2D). The nitrogen atom in the benzamide moiety and the oxygen atom in the center of GRL0617 (N01 and O7) can make hydrogen bonds (Fig 2B, S1 Fig). In all replicas, it was observed that the Tyr268 changes the orientation of its side chain and affects the conformation of the inhibitor. This residue on the tip of the BL2 loop can take the inhibitor out of its crystallographic conformation and lift the naphthalene moiety of the inhibitor. The changes in the orientation of the naphthalene moiety and the Tyr268 residue revealed this fact (Fig 2E and 2D). Then, water molecules could quickly get underneath the inhibitor and disrupt the interaction between the inhibitor and the residues of the binding site, especially the hydrogen bonds, and lifted it (Fig 2F) until it ultimately got out of the binding pocket (Fig 2G). The RMSD values of the inhibitor throughout the simulations (Fig 2A) indicated that it only takes very short amounts of time for the inhibitor to get from the crystallographic conformation to the unbound state, and the intermediate states in-between are not stable and do not last much. The total interaction energies of the protein-ligand complexes (Fig 2C), which are the sum of Lenard-Jones and electrostatic interaction energies, also suggest the same. However, in replica No 2, the interactions between the inhibitor and the protein got weaker, and simultaneously the structure of the BL2 loop got altered at about 40 ns (Fig 2A and 2C). The BL2 loop seems to play a very critical role in the unbinding process. In almost all replicas, the conformation alteration of this loop happened before the unbinding events of the inhibitor. The backbone RMSD values of the residues of the BL2 loop (Fig 2A) illustrate this role. A more effective inhibitor must be able to stop this loop from its natural fluctuations. Additionally, the Free Energy landscape analysis of the unbinding events (Fig 2H–2J) also showed that the intermediate states between the bound state and the unbound states are not stable, and the only stable state is the inhibitor in the crystallographic (native) conformation in which the protein-ligand contact surfaces values are at maximum, and the ligand RMSD values are at their minimum. The movies of the unbinding pathway of the inhibitors can be found in the supplementary materials.

Fig 2 — **(A)** The RMSD values of the inhibitor in three replicas (Displayed in Å) and the backbone RMSD values of residues of the BL2 loop in three replicas (Displayed in nm) throughout the simulations. **(B)** The 2D structure of GRL0617 was obtained from PDB. **(C)** The Total interaction Energies of the protein-ligand complexes throughout the simulations. **(D)** The native state of the GRL0617 in the crystallographic conformation and the interactions with the residues of the binding pocket (frame at 0 ns). **(E)** An intermediate state of GRL0617 in the unbinding pathway where the Tyr268 residue forced the inhibitor to change its native conformation (2^nd replica, frame in 68 ns). **(F)** In another intermediate state, the entire molecule is lifted, and almost all essential bonds and interactions between the ligand and the residues are water-mediated and broken (3^rd replica, frame in 85 ns). **(G)** The unbound state of the inhibitor is entirely free and solvated in the simulation box (1^st replica, frame in 100 ns). **(H)** The free energy landscape (FEL) representation of the unbinding pathway of the GRL0617, replica No 1. **(I)** The free energy landscape (FEL) representation of the unbinding pathway of the GRL0617, replica No 2. **(J)** The free energy landscape (FEL) representation of the unbinding pathway of the GRL0617, replica No 3. Letter “N” indicates the native crystallographic conformation.

In the PLP_Snyder441-Plpro complex, the duration times of the unbinding events were considerably shorter than the GRL0617, despite the fact that the only difference is the position of the amid group on the benzamide moiety (Fig 3B). Like the GRL0617, two hydrogen bonds with the backbone and the side chain of Gln269 were observed (Fig 3D). In all of the three replicas performed, it was observed that the movements of the BL2 loop affected the inhibitors (Fig 3A). In the native form, the BL2 loop folds towards the center of Plpro, and it has a curved shape. In the SuMD simulations, it was observed that the BL2 gradually took some distance from the enzyme and became flat. It also dragged the inhibitor away from the binding site since the inhibitor can make strong interactions with the residues on the tip of the BL2 loop (Fig 3E and 3F). In this conformation of the BL2 loop, the inhibitor is fully exposed to water molecules and very vulnerable. Then, the interactions got broken in a short amount of time, and the inhibitor got unbound (Fig 3G). This mode of the unbinding pathway only happened in replica No 2 and 3, where the flatting motion of the BL2 loop was observed. The early occurrence of this motion led to the short unbinding event in replica No 2 and 3, about 70 and 30 ns, respectively. The total interaction energy values (Fig 3C), especially in replica No 2, in which the BL2 loop flattened, showed that this motion of the BL2 loop dramatically decreased the interaction energies and made it easier for the inhibitor to unbind. FES analysis of the three replicas (Fig 3H–3J) also illustrated the intermediate state where the inhibitor sticks to the flattened BL2 loop. This intermediate state is not stable, and the interaction energies are not sufficient to hold the inhibitor.

Fig 3 — **(A)** The RMSD values of the inhibitor in three replicas (Displayed in Å) and the backbone RMSD values of residues of the BL2 loop in three replicas (Displayed in nm) throughout the simulations. **(B)** The 2D structure of PLP_Snyder441 was obtained from PDB. **(C)** The Total interaction Energies of the protein-ligand complexes throughout the simulations. (D) The bound state of the PLP_Snyder441 in the crystallographic (native) conformation and the interactions with the residues of the binding pocket (frame at 0 ns). **(E)** An intermediate state of PLP_Snyder441 in the unbinding pathway where the BL2 loop gradually starts to take some distance from the enzyme (1^st replica, frame in 150 ns). **(F)** Another intermediate state where the BL2 loop is entirely flat and the inhibitor is stuck to the residues on the tip of the loop (Tyr268 and the Gln269) and is almost solvated (2^nd replica, frame in 55 ns). **(G)** The unbound state of the inhibitor is entirely free and solvated in the simulation box. **(H)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder441, replica No 1. **(I)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder441, replica No 2. **(J)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder441, replica No 3. Letter “N” indicates the native crystallographic conformation.

In the PLP_Snyder495-Plpro complex, the unbinding events happened in very short amounts of time, ranging from 15 to 40 ns (Fig 4A). The addition of two carbamoyl groups to benzamide moiety in the structure of PLP_Snyder495 (Fig 4B) enables it to make extra hydrogen bonds with the residues which are not on the BL2 loop, such as Glu 167 (Fig 4D). Like the previous inhibitors, hydrogen bonds were observed with the residues of the BL2 loop in the crystallographic conformation. Although the hydrogen bonds with the Glu167 are strong and can hold the inhibitor, the flatting motion of the BL2 loop can still drag the inhibitor away from the binding pocket (Fig 4E and 4F). On the other hand, these extra hydrogen bonds can even force the inhibitor to lift, and in the meanwhile, the interactions can get water-mediated (Fig 4E). These events altogether caused the inhibitor to get out of its native conformation and unbind eventually (Fig 4G). The FES analysis also showed that the inhibitor occupies two intermediate states during the unbinding pathway. It can either be stuck to the tip of the BL2 loop or lift and maintain its hydrogen bonds with the Glu167 (Fig 4H–4J).

In the last complex, PLP_Snyder530-Plpro, in replica No 1 and 2, the conformational changes of the BL2 loop are considerably less than replica No 1. the duration times of the unbinding events was nearly the same as the GRL0617-Plpro complex (Fig 5A). The two inhibitors are very similar in structure and behavior, although the PLP_snyder530 has an acryloylamino group instead of a single amid group on the benzamide moiety (Fig 5B). The interactions present in the native conformation were also the same, but with the difference that in the PLP_Snyder530, the oxygen atom of the acryloylamino group makes a hydrogen bond with the side chain of the Gln269, which is a stronger bond (Fig 5D). The intermediate states observed during the unbinding pathway were almost the same as the previous inhibitors (Fig 5E and 5F), and the FES analysis also illustrates that these intermediate states are not stable and do not last much (Fig 5H–5J). The same behavior and motions of the BL2 loop were seen until the inhibitor was entirely unbound (Fig 5G). The total interaction energy values also suggest that the conformational alterations of the BL2 loop directly affect the binding affinity of the inhibitor (Fig 5C).

Fig 5 — **(A)** The RMSD values of the inhibitor in three replicas (Displayed in Å) and the backbone RMSD values of residues of the BL2 loop in three replicas (Displayed in nm) throughout the simulations. **(B)** The 2D structure of PLP_Snyder530 was obtained from PDB. **(C)** The Total interaction Energies of the protein-ligand complexes throughout the simulations. **(D)** The bound state of the PLP_Snyder530 in the crystallographic (native) conformation and the interactions with the residues of the binding pocket (frame at 0 ns). **(E)** An intermediate state of PLP_Snyder530 in the unbinding pathway in which the naphthalene moiety had turned and is out of the crystallographic (native) binding conformation (3rd replica, frame in 50 ns). **(F)** Another intermediate state where the BL2 loop is completely flat and the inhibitor is stuck to the residues on the tip of the loop (Tyr268 and the Gln269) (2^nd replica, frame in 60 ns). **(G)** The unbound state of the inhibitor that is completely free and solvated in the simulation box. **(H)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder530, replica No 1. **(I)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder530 replica No 2. **(J)** The free energy landscape (FEL) representation of the unbinding pathway of the PLP_Snyder530, replica No 3. Letter “N” indicates the native crystallographic conformation.

In the crystallographic conformation, residues such as Tyr264, Tyr268, Gln269, Arg166, and Leu 162 have the role of stabilizing the inhibitors and have the most interaction energies with the inhibitors (S2 and S3 Figs). Overall, it was found that the unbinding pathways of these inhibitors from the binding pocket are triggered either by interferences of the residues such as Tyr268 or by the changing conformations of the BL2 loop. In these two factors mentioned above, the natural fluctuations of this family of inhibitors can quickly leave the binding site. The most significant contributing factor discovered in the unbinding pathways of all inhibitors was the roles and the behavior of the BL2 loop and the residues on its tip, Tyr268 and Gln269 (S4 Fig). The great movements of this loop are for recognizing P2-P4 of the LXGG motif of substrate [34]. It was also perceived in the results that these movements are not just for trapping the substrate but also for throwing the product out. The crystallographic structures of the complexed or apo forms of the Plpro enzyme are all determined at 100 K. In these low temperatures, this loop will probably show the closed conformation, and even in the apo form (Fig 1), it is not fully open. The only available crystallographic structure of the apo form of Plpro, determined in the room temperature to this date, was the PDB code 6XG3. Even in this structure, the closed form of the BL2 loop is present. However, in the unbinding pathways, it was observed that this loop opens much more than the reported crystallographic structures (Fig 6A). The RMSF values of the residues (Fig 6B) also showed that some areas of the enzyme, such as the Ub binding domain and the BL2 loop, have high fluctuations. The presence of the ligand in the active site may probably lower these fluctuations (Fig 6B, S5 Fig). In the unbinding pathways, the BL2 loop showed that it could drag the inhibitors away from the binding pocket and make them exposed to the water molecules. The residues of the BL2 loop, such as Tyr268 and Gln269, can also make strong interactions such as hydrogen bonds and Pi-stacking for keeping the inhibitors glued to the tip of the BL2 loop (Figs 3F, 5F and 6F). This path line where the inhibitor stayed connected to the tip of the BL2 loop and the BL2 loop got flattened, was one of the unbinding pathways discovered in this study. We believe that the flexibility of the BL2 loop is a natural behavior, and it certainly works at a specific rate to facilitate the activity of the enzyme, recognizing, trapping, and throwing out the resulting product. Disabling this movement might also be a route to inhibit the activity of the enzyme.

Fig 6 — (A) the crystallographic structures of the Plpro are superimposed to compare the flexibility of the BL2 loop and the degree of its opening mechanism. The fully open structure of the BL2 (Black), which was achieved from the unbinding pathways and in the presence of the inhibitor, showed that the distance between the Cα atoms of the Tyr268 on the tip of the BL2 loop in each structure reaches 11.5 Å. (B) the RMSF values of the residues of the Plpro enzyme during the unbinding pathways of the inhibitors and in the apo form of the enzyme, with respect to the important regions of the enzyme.

The main goal of this study was to find the details of the unbinding pathway of Plpro inhibitors and understand the governing factors to find ways to improve these compounds. By analyzing the results and inspecting the protein-inhibitor complexes and the unbinding pathways, we found that although many bonds and interactions are formed between the inhibitors and the residues of the binding pocket, which make them very stable, the natural fluctuation of the BL2 loop can easily displace the inhibitors and make them unbind. One of the best solutions to improve these naphthalene-based inhibitors is adding substitution groups or moieties to increase interaction with regions other than the BL2 loop. If the inhibitors make more interactions with the BL2 loop, it would be easier for this loop to displace them. Therefore, less interaction with the BL2 loop and more bonds and interactions with the inner parts of the binding pocket is needed. Among the synthesized inhibitors by Osipiuk et al. [23], PLP_Snyder495 had extra groups on the benzamide moiety that could make strong hydrogen bonds with the Glu167. Although this residue is not on the BL2 loop and located on the upper side of the binding pocket, it can make strong hydrogen bonds with the PLP-Snyder495 (Fig 4D). However, this residue is fully exposed to water molecules. The hydrogen bonds formed between the inhibitor and this residue can easily get water-mediated and broken; thus, this compound had the worst performance in our simulations and left the binding pocket in very short amounts of time (Table 1). Making strong interactions with the correct residues is the key. All of these inhibitors can strongly bind to the BL2 loop. We believe that minimizing interactions with the BL2 loop and maximizing interactions with the inner parts of the binding pocket where there is more limited access to water molecules is the best way to improve these inhibitors. GRL0617 has proven to inhibit the cytopathogenic effect of the virus [49]. Optimizing and improving this potent inhibitor is the route to an efficacious treatment for Covid-19. The Details understood from this study can be used for this purpose.

Conclusion

Plpro has proved to be a tremendous molecular target for fighting SARS-CoV-2. Inhibition of this enzyme by GRL0617 and its derivatives has inhibited the virus’s cytopathogenic effect and making them highly potential. However, their efficacy is not sufficient enough, and more effective inhibitors are urgently needed. In this work, the SuMD method enabled us to achieve multiple unbinding events of known Plpro inhibitors and understand vital details that can help improve the efficacy of these inhibitors. We found that the BL2 loop has natural motions that are probably very important in the enzyme activity. Improving the available inhibitors by considering the motions of this loop and the residues involved will produce more effective and more efficacious inhibitors.

Supporting information

S1 Fig. The distance between the atoms contributing in important hydrogen bonds in the protein-ligand complexes.

(A) The important hydrogen bonds in the GRL0617-Plpro complex. (B) The important hydrogen bonds in PLP-Snyder441-Plpro complex. (C) The important hydrogen bonds in PLP_Snsyder495-Plpro complex. (D) The important hydrogen bonds in PLP_Snsyder530-Plpro complex.

(TIF)

Click here for additional data file.^{(4MB, tif)}

S2 Fig. The interaction energy contribution of the residues in contact with the inhibitor in the GRL0617-Plpro complex.

A) replica No 1. (B) replica No 2. (C) replica No 3.

(TIF)

Click here for additional data file.^{(4.4MB, tif)}

S3 Fig. The interaction energy contribution of the residues in contact with the inhibitor in the PLP_Snyder495-Plpro complex.

(A) replica No 1. (B) replica No 2. (C) replica No 3.

(TIF)

Click here for additional data file.^{(2.8MB, tif)}

S4 Fig. The VdW and electrostatic interaction energies of each replica in the unbinding pathways.

(A) GRL0617-Plpro complex. (B) PLP-Snyder441-Plpro complex. (C) PLP_Snsyder495-Plpro complex. (D) PLP_Snsyder530-Plpro complex.

(TIF)

Click here for additional data file.^{(3.9MB, tif)}

S5 Fig. The backbone RMSD values of the Plpro enzyme in apo form.

The duration of the simulation was 100 ns.

(TIF)

Click here for additional data file.^{(1.9MB, tif)}

S1 File. 7cmd-rep1.mp4, the unbinding pathway of GRL0617 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(49.6MB, mp4)}

S2 File. 7JIT-rep1.mp4, the unbinding pathway of PLP_Snyder495 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(8.2MB, mp4)}

S3 File. 7JN2-rep1.mp4, the unbinding pathway of PLP_Snyder441 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(46.7MB, mp4)}

S4 File. 7JIW-rep1.mp4, the unbinding pathway of PLP_Snyder530 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(26.8MB, mp4)}

Data Availability

Farzin Sohraby, & Hassan Aryapour. (2021). Dataset of the Article "Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation". http://doi.org/10.5281/zenodo.4726944.

Funding Statement

This investigation was supported by the grant number 99-213-1 from Golestan University, Gorgan, Iran.

References

1.Chakraborty I, Maity P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of The Total Environment. 2020;728:138882. 10.1016/j.scitotenv.2020.138882 [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020;6(3):315–31. 10.1021/acscentsci.0c00272 [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Khan Z, Karataş Y, Ceylan AF, Rahman H. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. Le Pharmacien Hospitalier et Clinicien. 2020. 10.1016/j.phclin.2020.06.003. [DOI] [Google Scholar]
4.Jean S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43. Epub 04/04. 10.1016/j.jmii.2020.03.034 . [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955–. Epub 03/28. 10.1016/j.ijantimicag.2020.105955 . [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, et al. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Journal of Medicinal Chemistry. 2020. 10.1021/acs.jmedchem.0c00502 [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Cohen MS. Hydroxychloroquine for the Prevention of Covid-19—Searching for Evidence. New England Journal of Medicine. 2020;383(6):585–6. 10.1056/NEJMe2020388 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569–78. 10.1016/S0140-6736(20)31022-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. 2020;73(9):593–602. 10.1038/s41429-020-0336-z [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Tao Y, Tang LV, Hu Y. Treatments in the COVID-19 pandemic: an update on clinical trials. Expert Opinion on Emerging Drugs. 2020;25(2):81–8. 10.1080/14728214.2020.1773431 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;117(17):9490. 10.1073/pnas.2004168117 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates. 2020;53:100719. 10.1016/j.drup.2020.100719 [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020:10.1016/j.mjafi.2020.08.004. 10.1016/j.mjafi.2020.08.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020. 10.1016/j.eng.2020.03.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences. 2020:202014441. 10.1073/pnas.2014441117 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19—Final Report. New England Journal of Medicine. 2020. 10.1056/NEJMoa2007764 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity. Journal of Virology. 2004;78(24):13600. 10.1128/JVI.78.24.13600-13612.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Lim KP, Ng LF, Liu DX. Identification of a novel cleavage activity of the first papain-like proteinase domain encoded by open reading frame 1a of the coronavirus Avian infectious bronchitis virus and characterization of the cleavage products. J Virol. 2000;74(4):1674–85. Epub 2000/01/22. 10.1128/jvi.74.4.1674-1685.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Clementz MA, Chen Z, Banach BS, Wang Y, Sun L, Ratia K, et al. Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases. Journal of Virology. 2010;84(9):4619. 10.1128/JVI.02406-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Lindner HA, Lytvyn V, Qi H, Lachance P, Ziomek E, Ménard R. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys. 2007;466(1):8–14. Epub 07/14. 10.1016/j.abb.2007.07.006 . [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Békés M, Rut W, Kasperkiewicz P, Mulder MP, Ovaa H, Drag M, et al. SARS hCoV papain-like protease is a unique Lys48 linkage-specific di-distributive deubiquitinating enzyme. The Biochemical journal. 2015;468(2):215–26. Epub 2015/03/15. 10.1042/BJ20141170 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol. 2005;79(24):15189–98. Epub 2005/11/25. 10.1128/JVI.79.24.15189-15198.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Osipiuk J, Azizi S-A, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, et al. structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. bioRxiv. 2020:2020.08.06.240192. 10.1101/2020.08.06.240192 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences. 2008;105(42):16119. 10.1073/pnas.0805240105 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry. 2016;59(14):6595–628. 10.1021/acs.jmedchem.5b01461 [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Wang T, Wu MB, Zhang RH, Chen ZJ, Hua C, Lin JP, et al. Advances in Computational Structure-Based Drug Design and Application in Drug Discovery. Curr Top Med Chem. 2016;16(9):901–16. 10.2174/1568026615666150825142002 . [DOI] [PubMed] [Google Scholar]
27.Heifetz A, Southey M, Morao I, Townsend-Nicholson A, Bodkin MJ. Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery. Methods Mol Biol. 2018;1705:375–94. 10.1007/978-1-4939-7465-8_19 . [DOI] [PubMed] [Google Scholar]
28.Gohlke H, Hergert U, Meyer T, Mulnaes D, Grieshaber MK, Smits SH, et al. Binding region of alanopine dehydrogenase predicted by unbiased molecular dynamics simulations of ligand diffusion. J Chem Inf Model. 2013;53(10):2493–8. 10.1021/ci400370y . [DOI] [PubMed] [Google Scholar]
29.Sohraby F, Javaheri Moghadam M, Aliyar M, Aryapour H. A boosted unbiased molecular dynamics method for predicting ligands binding mechanisms: Probing the binding pathway of dasatinib to Src-kinase. Bioinformatics. 2020. 10.1093/bioinformatics/btaa565 [DOI] [PubMed] [Google Scholar]
30.Sohraby F, Aryapour H. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. Seminars in Cancer Biology. 2020. 10.1016/j.semcancer.2020.04.007 [DOI] [PubMed] [Google Scholar]
31.Sabbadin D, Salmaso V, Sturlese M, Moro S. Supervised Molecular Dynamics (SuMD) Approaches in Drug Design. Methods Mol Biol. 2018;1824:287–98. 10.1007/978-1-4939-8630-9_17 . [DOI] [PubMed] [Google Scholar]
32.Deganutti G, Moro S, Reynolds CA. A Supervised Molecular Dynamics Approach to Unbiased Ligand–Protein Unbinding. Journal of Chemical Information and Modeling. 2020;60(3):1804–17. 10.1021/acs.jcim.9b01094 [DOI] [PubMed] [Google Scholar]
33.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–42. 10.1093/nar/28.1.235 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Gao X, Qin B, Chen P, Zhu K, Hou P, Wojdyla JA, et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharmaceutica Sinica B. 2020. 10.1016/j.apsb.2020.08.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. 10.1002/jcc.20084 . [DOI] [PubMed] [Google Scholar]
36.Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. 10.1016/j.softx.2015.06.001. [DOI] [Google Scholar]
37.Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. Journal of the American Chemical Society. 1996;118(45):11225–36. 10.1021/ja9621760 [DOI] [Google Scholar]
38.Sousa da Silva AW, Vranken WF. ACPYPE—AnteChamber PYthon Parser interfacE. BMC Res Notes. 2012;5:367. 10.1186/1756-0500-5-367 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. The Journal of chemical physics. 1983;79(2):926–35. 10.1063/1.445869 [DOI] [Google Scholar]
40.Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry. 1997;18(12):1463–72. [DOI] [Google Scholar]
41.Darden T, York D, Pedersen L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of chemical physics. 1993;98(12):10089–92. 10.1063/1.464397 [DOI] [Google Scholar]
42.Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. The Journal of chemical physics. 2007;126(1):014101. 10.1063/1.2408420 . [DOI] [PubMed] [Google Scholar]
43.Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of applied physics. 1981;52(12):7182–90. 10.1063/1.328693 [DOI] [Google Scholar]
44.Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. Journal of Molecular Graphics. 1996;14(1):33–8. 10.1016/0263-7855(96)00018-5 [DOI] [PubMed] [Google Scholar]
45.Kraus D. Consolidated data analysis and presentation using an open-source add-in for the Microsoft Excel® spreadsheet software. Medical Writing. 2014;23(1):25–8. 10.1179/2047480613Z.000000000181 [DOI] [Google Scholar]
46.Hunter JD. Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering. 2007;9(3):90–5. 10.1109/MCSE.2007.55 [DOI] [Google Scholar]
47.Kumari R, Kumar R, Lynn A. g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations. Journal of Chemical Information and Modeling. 2014;54(7):1951–62. 10.1021/ci500020m [DOI] [PubMed] [Google Scholar]
48.Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral research. 2015;115:21–38. Epub 12/29. 10.1016/j.antiviral.2014.12.015 . [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020. 10.1038/s41586-020-2601-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW, Bernardini JP, et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. The EMBO Journal. 2020;39(18):e106275. 10.15252/embj.2020106275 [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Bosken YK, Cholko T, Lou Y-C, Wu K-P, Chang C-eA. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease. Frontiers in Molecular Biosciences. 2020;7(174). 10.3389/fmolb.2020.00174 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0251910.r001

Decision Letter 0

Emilio Gallicchio

14 Apr 2021

PONE-D-21-08289

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular dynamics simulation

PLOS ONE

Dear Dr. Aryapour,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address each of the points raised by the reviewers and note in the cover letter the corresponding revisions of the manuscript. Include in the cover letter detailed responses to the comments of the reviewers.

Please submit your revised manuscript by May 29 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the reviewers. You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Emilio Gallicchio, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript
A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Comments for the Authors

The outbreak and spread of COVID-19 diseases caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now is well-known as a global concern to the public health worldwide. Most infected people develop asymptomatic symptoms or mild to moderate illness and recover without hospitalization. However, for these of severe cases will have worsening dyspnea accompanied by hypoxemia and further turn to progressive respiratory failure, which can be lethal. Vaccine can prevent the spread of COVID-19 for the uninfected individuals. However, for these SARS-CoV-2 infected patients with acute diseases, pharmaceutic intervention with significant therapeutic efficiency would be an essential antiviral treatment strategy. The papain-like protease (PLpro) of SARS-CoV-2 is a highly versatile enzyme that processes viral polyproteins to generate a functional replicase complex and enable viral spread, also essential for cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses. Inhibition of SARS-CoV-2 PLpro with inhibitor could be a potential therapeutic strategy through impeding viral replication in infected cells. In this study, Farzin et al. performed Supervised Molecular Dynamics (SuMD) simulations to decipher the unbinding pathway of SARS-CoV-2 PLpro and its four inhibitors including GRL0617 and its derivates. The simulation stability of SARS-CoV-2 PLpro and GRL0617 outperforms those of the other three, in agreement with the experimental IC50 data. The 2D free energy changes caused by the binding of inhibitors were calculated. Their respective intermediate binding poses, protein-ligand interactions such as hydrogen bond changes over time, RMSF of PLpro residues at holo state were analyzed. In summary, the work is perspectively important and properly descripted. It provides useful conclusions about how GRL0617 and its derivates disassociated with the PLpro binding, in particular, the major role of Tyr268 and Gln269 residues of the BL2 loop in the unbinding pathways.

There are several points described below,

1.For each inhibitor, 3 series of SuMD simulations were performed. However, the 2D free energy profiles are likely not converged, as new minima emerged in each of three maps, for instance, Fig. 5h-j. More series of SuMD simulations should be needed.

2. Although the authors mentioned binding free energy calculation by MM/PBSA method, however, I did not find the calculation results. Also, the authors also estimated the contribution of each amino acids, as shown in Supplementary Figs. 2-3, however, the authors did not describe in the manuscript about how these contributions were estimated, by free energy decomposition method?

3.I suggest to highlight the catalytic triad and the BL2 loop with different color in the upper panel of Fig. 1, while yellow colored residues interacting with GRL0617 ligand should be labeled too in the lower panel of Fig. 1. In addition, BL2 loop should be defined, from which residue to which residue?

4.(1)What is the reference structure used for RMSD calculation in Figs. 2-4a?

(2)I suggest to split the total interaction so as to also include the ele and vdw interactions in Figs. 2-4c to show their changes.

(3)The distance of hydrogen bonds in Figs. 2-4 should be labeled.

(4)There are many intermediate states during a MD simulation, which frames were extracted as Figs. 2-4e,f? Please clarify. It is important to find these key intermediate states correctly for each inhibitor, so that their comparisons were fair.

(5)Did the author extract out the structures from the minima of three free energy landscapes in Figs. 2-4h-j? These metastable structures should be compared and discussed.

(6)For each inhibitor, did three series SuMD show the same trajectory path line? I suggest the authors provide three trajectory path lines with three colors, to see if the inhibitor exit the binding pocket with different pathways.

(7)The crystallographic (native) conformation should be marked in Fig.s 2-4h-j.

5.For PLP_Snyder441-Plpro complex, the authors mentioned that “In all of the three replicas performed, it was observed that the movements of the BL2 loop had a direct effect on the inhibitors (Fig. 3a).” However, as shown in Fig. 3a, the replica 3 seems an opposite case. Because although BL2 dramatically shifted at ~8 ns, PLP_Snyder441 looked stable over the whole MD time. The reason should be tracked by analyzing the extracted structures.

6.The authors should run a direct MD simulation for SARS-CoV-2 PLpro at apo state, and calculate RMSF for each residue to show the nature flexibility particularly for BL2 loop to support the point that “The presence of the ligand in the active site may probable lower these fluctuations”.

7.In Fig. 6, the binding ligands of crytal structure (green) and MD structure (black) should be presented using the same color with their corresponding proteins.

Minor issues:

1. “The RMSD values of the inhibitor throughout the simulations (Fig. 2a) indicated that it only takes very short amounts of time for the inhibitor to get from the crystallographic conformation to the unbound state”, the “amounts” here is subscript, please correct.

2. Please provide legends for movies as well. The movies should be cited in the main text properly.

3. “On the other hand, these extra hydrogen bonds can even force the inhibitor to lift up and in the meanwhile the interactions can get water-mediated (Fig. 4c).” “Fig. 4c” should be “Fig. 4e”.

Reviewer #2: The article is straightforward and for most of the parts clear. The impact that it would provide is significant since it provides insight into potential drug discovery against COVID-19. I therefore believe that it is valuable, and it should be published. However, it needs some revisions:

1. In Table 1 the authors claim “In terms of duration, the more potent GRL0617 showed better performance than the others, except for the PLP_Snyder530, and the already published activity assays also suggest the same. However, comparing the duration times of the unbinding events is not a correct way to compare the potency of the inhibitors.”

If “comparing the duration times of the unbinding events is not a correct way to compare the potency of the inhibitors”, what is the point of even including Table 1?

2. In figure 1, none of the ligand-receptor interactions (H-bonds and pi-stacking) are depicted.

3. In all the figures, I notice inconsistencies: the BL2 is not always labelled, some key residues are not always labelled, pi-stacking interactions are never depicted.

4. In the last portion of the discussion I notice another contradiction. The authors claim: “Among the synthesized inhibitors by Osipiuk et al.[23], PLP_Snyder495 had extra groups on the benzamide moiety that could make strong hydrogen bonds with the Glu167 which is not on the BL2 loop. However, this residue is fully exposed to water molecules and the hydrogen bonds can easily get water-mediated and broken and as a result, this compound had the worst performance in our simulations and left the binding pocket in very short amounts of time (Table 1). We believe that minimizing interactions with the BL2 loop and maximizing interactions with the inner parts of the binding pocket where there is more limited access to water molecules is the best way to improve these inhibitors.”

Glu 167 seems to be in the inner part of the pocket and yet the molecule does not bind strongly enough. This seems to contradict the last sentence. Can you please explain?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Pierpaolo Cordone

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 19;16(5):e0251910. doi: 10.1371/journal.pone.0251910.r002

Author response to Decision Letter 0

29 Apr 2021

Dear Reviewers;

Thank you for reviewing our manuscript. We appreciate your constructive comments for improving the article. Your comments have been fully applied to the text and the figures of the manuscript. It is a great honor to be a part of your prestigious journal.

Sincerely,

Hassan Aryapour

Comments to the Author

Answers were added

Reviewer #1: The outbreak and spread of COVID-19 diseases caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now is well-known as a global concern to the public health worldwide. Most infected people develop asymptomatic symptoms or mild to moderate illness and recover without hospitalization. However, for these of severe cases will have worsening dyspnea accompanied by hypoxemia and further turn to progressive respiratory failure, which can be lethal. Vaccine can prevent the spread of COVID-19 for the uninfected individuals. However, for these SARS-CoV-2 infected patients with acute diseases, pharmaceutic intervention with significant therapeutic efficiency would be an essential antiviral treatment strategy. The papain-like protease (PLpro) of SARS-CoV-2 is a highly versatile enzyme that processes viral polyproteins to generate a functional replicase complex and enable viral spread, also essential for cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses. Inhibition of SARS-CoV-2 PLpro with inhibitor could be a potential therapeutic strategy through impeding viral replication in infected cells. In this study, Farzin et al. performed Supervised Molecular Dynamics (SuMD) simulations to decipher the unbinding pathway of SARS-CoV-2 PLpro and its four inhibitors including GRL0617 and its derivates. The simulation stability of SARS-CoV-2 PLpro and GRL0617 outperforms those of the other three, in agreement with the experimental IC50 data. The 2D free energy changes caused by the binding of inhibitors were calculated. Their respective intermediate binding poses, protein-ligand interactions such as hydrogen bond changes over time, RMSF of PLpro residues at holo state were analyzed. In summary, the work is perspectively important and properly descripted. It provides useful conclusions about how GRL0617 and its derivates disassociated with the PLpro binding, in particular, the major role of Tyr268 and Gln269 residues of the BL2 loop in the unbinding pathways.

There are several points described below,

Question #1: For each inhibitor, 3 series of SuMD simulations were performed. However, the 2D free energy profiles are likely not converged, as new minima emerged in each of three maps, for instance, Fig. 5h-j. More series of SuMD simulations should be needed.

Answer #1: The FEL profiles may not converge, and it is because each of the inhibitors may have many routes for their unbinding pathways. However, the first steps of unbinding pathways in the three replicas of each inhibitor were almost the same. In each replica, the main player is the fluctuation of the BL2 loop and the two most important residues, Tyr268 and Gln269.

Question #2: Although the authors mentioned binding free energy calculation by MM/PBSA method, however, I did not find the calculation results. Also, the authors also estimated the contribution of each amino acids, as shown in Supplementary Figs. 2-3, however, the authors did not describe in the manuscript about how these contributions were estimated, by free energy decomposition method?

Answer #2: The results of the MMPBSA method for each replica and each protein-inhibitor complex are presented in Fig2.c, Fig3.c, Fig4.c, and Fig5.c, and it is represented as protein-ligand interaction energies. The contribution of each residue during the simulations was calculated by the sum of VdW and electrostatic interaction energies between important residues and the inhibitors during the unbinding pathway. The data was extracted from the trajectory and energy files of simulation using Gromacs’s modules such as “gmx rerun” and “gmx energy”. The related information was added to the “Materials and Methods” section.

Question #3: I suggest to highlight the catalytic triad and the BL2 loop with different color in the upper panel of Fig. 1, while yellow colored residues interacting with GRL0617 ligand should be labeled too in the lower panel of Fig. 1. In addition, BL2 loop should be defined, from which residue to which residue?

Answer #3: The figure 1 does not only illustrate the position of the BL2 loop and the catalytic triad on the structure of the Plpro but showing the difference between the apo form and the complex form of this enzyme in the presence of the inhibitor, GRL0617 in the binding site. However, for more clarification, the range of the residues of the BL2 loop was added to the caption of the figure.

Questions #4.

What is the reference structure used for RMSD calculation in Figs. 2-4a?

(1) The reference for the calculation of the RMSD values is the crystallographic structure of the complexes.

(2) I suggest to split the total interaction so as to also include the ele and vdw interactions in Figs. 2-4c to show their changes.

(2) The divided interaction energies were provided as a supplementary figure, Sup Fig 4.

(3) The distance of hydrogen bonds in Figs. 2-4 should be labeled.

(3) Corrected

(4) There are many intermediate states during a MD simulation, which frames were extracted as Figs. 2-4e,f? Please clarify. It is important to find these key intermediate states correctly for each inhibitor, so that their comparisons were fair.

(4) Corrected

(5) Did the author extract out the structures from the minima of three free energy landscapes in Figs. 2-4h-j? These metastable structures should be compared and discussed.

(5) Yes. The frames shown in the figures were extracted according to the state of the inhibitor during the unbinding pathway.

(6) For each inhibitor, did three series SuMD show the same trajectory path line? I suggest the authors provide three trajectory path lines with three colors, to see if the inhibitor exit the binding pocket with different pathways.

(6) Due to the limitation of the SuMD simulation, the path line of the unbinding pathway of each inhibitor was almost the same.

(7) The crystallographic (native) conformation should be marked in Fig.s 2-4h-j.

(7) Added

Question #5: For PLP_Snyder441-Plpro complex, the authors mentioned that “In all of the three replicas performed, it was observed that the movements of the BL2 loop had a direct effect on the inhibitors (Fig. 3a).” However, as shown in Fig. 3a, the replica 3 seems an opposite case. Because although BL2 dramatically shifted at ~8 ns, PLP_Snyder441 looked stable over the whole MD time. The reason should be tracked by analyzing the extracted structures.

Answer #5: in the case of PLP-Snyder441, the structure of the BL2 loop changed significantly, as you mentioned. This structural change led to the water-mediation of the interactions of the inhibitor and the residues and caused it to unbind moments later. It is better to say that in this case, rep3, the movements of the BL2 loop had rather indirect effects on the unbinding pathway of this inhibitor. However, its crucial influence on the unbinding pathway is undeniable.

Question #6: The authors should run a direct MD simulation for SARS-CoV-2 PLpro at apo state, and calculate RMSF for each residue to show the nature flexibility particularly for BL2 loop to support the point that “The presence of the ligand in the active site may probable lower these fluctuations”.

Answer #6: The Apo state of Plpro has been simulated for 100 ns, and RMSF values have been added to Fig 6b.

Question #7: In Fig. 6, the binding ligands of crytal structure (green) and MD structure (black) should be presented using the same color with their corresponding proteins.

Answer #7: the purpose of Fig 6a was to show the severity of the BL2 loop fluctuations. The structures were chosen for this analysis, 6W9C and 6XG3, are the apo forms of the protein, and the black structure is a simulated model of Plpro when the ligand was about to leave the binding pocket and the end of the unbinding pathway. Similar structure can be found in Fig 5f.

Minor issues:

(1). “The RMSD values of the inhibitor throughout the simulations (Fig. 2a) indicated that it only takes very short amounts of time for the inhibitor to get from the crystallographic conformation to the unbound state”, the “amounts” here is subscript, please correct.

(1) corrected

(2). Please provide legends for movies as well. The movies should be cited in the main text properly.

(2) Added

(3). “On the other hand, these extra hydrogen bonds can even force the inhibitor to lift up and in the meanwhile the interactions can get water-mediated (Fig. 4c).” “Fig. 4c” should be “Fig. 4e”.

(3) Corrected

Question #1: In Table 1 the authors claim “In terms of duration, the more potent GRL0617 showed better performance than the others, except for the PLP_Snyder530, and the already published activity assays also suggest the same. However, comparing the duration times of the unbinding events is not a correct way to compare the potency of the inhibitors. ”If “comparing the duration times of the unbinding events is not a correct way to compare the potency of the inhibitors”, what is the point of even including Table 1?

Answer #1: The point of including table 1 was to show the potency of the inhibitors in wet-lab experiments and their activity against Plpro. However, some correlations can be found between the duration times and the activity of the inhibitors. The sentence in the text of the manuscript has been corrected accordingly.

Question #2: In figure 1, none of the ligand-receptor interactions (H-bonds and pi-stacking) are depicted.

Answer #2: No, none of the interactions are shown. Because the purpose of this figure was only to show the position of the BL2 loop and the binding site of the inhibitors, and the fluctuations and the movements of the BL2 loop in apo form and in the presence of the inhibitor. The protein-inhibitor interactions in the crystallographic form are all shown in the “d” section of each figure.

Question #3: In all the figures, I notice inconsistencies: the BL2 is not always labelled, some key residues are not always labelled, pi-stacking interactions are never depicted.

Answer #3: Only essential labels and details were added to each figure to avoid putting packed labels and make the figures very crowded. All of the essential information needed to understand the data is present in the figures. However, more details and labels have been added in the revision.

Question #4: In the last portion of the discussion, I notice another contradiction. The authors claim: “Among the synthesized inhibitors by Osipiuk et al.[23], PLP_Snyder495 had extra groups on the benzamide moiety that could make strong hydrogen bonds with the Glu167 which is not on the BL2 loop. However, this residue is fully exposed to water molecules and the hydrogen bonds can easily get water-mediated and broken and as a result, this compound had the worst performance in our simulations and left the binding pocket in very short amounts of time (Table 1). We believe that minimizing interactions with the BL2 loop and maximizing interactions with the inner parts of the binding pocket where there is more limited access to water molecules is the best way to improve these inhibitors.”

Glu 167 seems to be in the inner part of the pocket and yet the molecule does not bind strongly enough. This seems to contradict the last sentence. Can you please explain?

Answer #4: As shown in Fig 4d, Glu167 is exposed to water molecules and located on the upper side of the binding pocket, not the inner parts. The inner parts are less exposed. The text of this bit has been changed to make it more understandable and clear.

________________________________________

PLoS One. doi: 10.1371/journal.pone.0251910.r003

Decision Letter 1

Emilio Gallicchio

6 May 2021

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

PONE-D-21-08289R1

Dear Dr. Aryapour,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Emilio Gallicchio, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

PLoS One. doi: 10.1371/journal.pone.0251910.r004

Acceptance letter

Emilio Gallicchio

10 May 2021

PONE-D-21-08289R1

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

Dear Dr. Aryapour:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Emilio Gallicchio

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. The distance between the atoms contributing in important hydrogen bonds in the protein-ligand complexes.

(TIF)

Click here for additional data file.^{(4MB, tif)}

S2 Fig. The interaction energy contribution of the residues in contact with the inhibitor in the GRL0617-Plpro complex.

A) replica No 1. (B) replica No 2. (C) replica No 3.

(TIF)

Click here for additional data file.^{(4.4MB, tif)}

S3 Fig. The interaction energy contribution of the residues in contact with the inhibitor in the PLP_Snyder495-Plpro complex.

(A) replica No 1. (B) replica No 2. (C) replica No 3.

(TIF)

Click here for additional data file.^{(2.8MB, tif)}

S4 Fig. The VdW and electrostatic interaction energies of each replica in the unbinding pathways.

(A) GRL0617-Plpro complex. (B) PLP-Snyder441-Plpro complex. (C) PLP_Snsyder495-Plpro complex. (D) PLP_Snsyder530-Plpro complex.

(TIF)

Click here for additional data file.^{(3.9MB, tif)}

S5 Fig. The backbone RMSD values of the Plpro enzyme in apo form.

The duration of the simulation was 100 ns.

(TIF)

Click here for additional data file.^{(1.9MB, tif)}

S1 File. 7cmd-rep1.mp4, the unbinding pathway of GRL0617 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(49.6MB, mp4)}

S2 File. 7JIT-rep1.mp4, the unbinding pathway of PLP_Snyder495 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(8.2MB, mp4)}

S3 File. 7JN2-rep1.mp4, the unbinding pathway of PLP_Snyder441 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(46.7MB, mp4)}

S4 File. 7JIW-rep1.mp4, the unbinding pathway of PLP_Snyder530 from the Plpro enzyme.

(MP4)

Click here for additional data file.^{(26.8MB, mp4)}

Data Availability Statement

[pone.0251910.ref001] 1.Chakraborty I, Maity P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of The Total Environment. 2020;728:138882. 10.1016/j.scitotenv.2020.138882 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref002] 2.Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020;6(3):315–31. 10.1021/acscentsci.0c00272 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref003] 3.Khan Z, Karataş Y, Ceylan AF, Rahman H. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. Le Pharmacien Hospitalier et Clinicien. 2020. 10.1016/j.phclin.2020.06.003. [DOI] [Google Scholar]

[pone.0251910.ref004] 4.Jean S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43. Epub 04/04. 10.1016/j.jmii.2020.03.034 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref005] 5.Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955–. Epub 03/28. 10.1016/j.ijantimicag.2020.105955 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref006] 6.Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, et al. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Journal of Medicinal Chemistry. 2020. 10.1021/acs.jmedchem.0c00502 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref007] 7.Cohen MS. Hydroxychloroquine for the Prevention of Covid-19—Searching for Evidence. New England Journal of Medicine. 2020;383(6):585–6. 10.1056/NEJMe2020388 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref008] 8.Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569–78. 10.1016/S0140-6736(20)31022-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref009] 9.Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. 2020;73(9):593–602. 10.1038/s41429-020-0336-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref010] 10.Tao Y, Tang LV, Hu Y. Treatments in the COVID-19 pandemic: an update on clinical trials. Expert Opinion on Emerging Drugs. 2020;25(2):81–8. 10.1080/14728214.2020.1773431 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref011] 11.Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;117(17):9490. 10.1073/pnas.2004168117 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref012] 12.Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates. 2020;53:100719. 10.1016/j.drup.2020.100719 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref013] 13.Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020:10.1016/j.mjafi.2020.08.004. 10.1016/j.mjafi.2020.08.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref014] 14.Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020. 10.1016/j.eng.2020.03.007 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref015] 15.Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences. 2020:202014441. 10.1073/pnas.2014441117 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref016] 16.Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19—Final Report. New England Journal of Medicine. 2020. 10.1056/NEJMoa2007764 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref017] 17.Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity. Journal of Virology. 2004;78(24):13600. 10.1128/JVI.78.24.13600-13612.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref018] 18.Lim KP, Ng LF, Liu DX. Identification of a novel cleavage activity of the first papain-like proteinase domain encoded by open reading frame 1a of the coronavirus Avian infectious bronchitis virus and characterization of the cleavage products. J Virol. 2000;74(4):1674–85. Epub 2000/01/22. 10.1128/jvi.74.4.1674-1685.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref019] 19.Clementz MA, Chen Z, Banach BS, Wang Y, Sun L, Ratia K, et al. Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like Proteases. Journal of Virology. 2010;84(9):4619. 10.1128/JVI.02406-09 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref020] 20.Lindner HA, Lytvyn V, Qi H, Lachance P, Ziomek E, Ménard R. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys. 2007;466(1):8–14. Epub 07/14. 10.1016/j.abb.2007.07.006 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref021] 21.Békés M, Rut W, Kasperkiewicz P, Mulder MP, Ovaa H, Drag M, et al. SARS hCoV papain-like protease is a unique Lys48 linkage-specific di-distributive deubiquitinating enzyme. The Biochemical journal. 2015;468(2):215–26. Epub 2015/03/15. 10.1042/BJ20141170 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref022] 22.Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol. 2005;79(24):15189–98. Epub 2005/11/25. 10.1128/JVI.79.24.15189-15198.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref023] 23.Osipiuk J, Azizi S-A, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, et al. structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. bioRxiv. 2020:2020.08.06.240192. 10.1101/2020.08.06.240192 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref024] 24.Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences. 2008;105(42):16119. 10.1073/pnas.0805240105 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref025] 25.Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung S-H. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry. 2016;59(14):6595–628. 10.1021/acs.jmedchem.5b01461 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref026] 26.Wang T, Wu MB, Zhang RH, Chen ZJ, Hua C, Lin JP, et al. Advances in Computational Structure-Based Drug Design and Application in Drug Discovery. Curr Top Med Chem. 2016;16(9):901–16. 10.2174/1568026615666150825142002 . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref027] 27.Heifetz A, Southey M, Morao I, Townsend-Nicholson A, Bodkin MJ. Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery. Methods Mol Biol. 2018;1705:375–94. 10.1007/978-1-4939-7465-8_19 . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref028] 28.Gohlke H, Hergert U, Meyer T, Mulnaes D, Grieshaber MK, Smits SH, et al. Binding region of alanopine dehydrogenase predicted by unbiased molecular dynamics simulations of ligand diffusion. J Chem Inf Model. 2013;53(10):2493–8. 10.1021/ci400370y . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref029] 29.Sohraby F, Javaheri Moghadam M, Aliyar M, Aryapour H. A boosted unbiased molecular dynamics method for predicting ligands binding mechanisms: Probing the binding pathway of dasatinib to Src-kinase. Bioinformatics. 2020. 10.1093/bioinformatics/btaa565 [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref030] 30.Sohraby F, Aryapour H. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. Seminars in Cancer Biology. 2020. 10.1016/j.semcancer.2020.04.007 [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref031] 31.Sabbadin D, Salmaso V, Sturlese M, Moro S. Supervised Molecular Dynamics (SuMD) Approaches in Drug Design. Methods Mol Biol. 2018;1824:287–98. 10.1007/978-1-4939-8630-9_17 . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref032] 32.Deganutti G, Moro S, Reynolds CA. A Supervised Molecular Dynamics Approach to Unbiased Ligand–Protein Unbinding. Journal of Chemical Information and Modeling. 2020;60(3):1804–17. 10.1021/acs.jcim.9b01094 [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref033] 33.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–42. 10.1093/nar/28.1.235 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref034] 34.Gao X, Qin B, Chen P, Zhu K, Hou P, Wojdyla JA, et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharmaceutica Sinica B. 2020. 10.1016/j.apsb.2020.08.014 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref035] 35.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. 10.1002/jcc.20084 . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref036] 36.Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. 10.1016/j.softx.2015.06.001. [DOI] [Google Scholar]

[pone.0251910.ref037] 37.Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. Journal of the American Chemical Society. 1996;118(45):11225–36. 10.1021/ja9621760 [DOI] [Google Scholar]

[pone.0251910.ref038] 38.Sousa da Silva AW, Vranken WF. ACPYPE—AnteChamber PYthon Parser interfacE. BMC Res Notes. 2012;5:367. 10.1186/1756-0500-5-367 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref039] 39.Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. The Journal of chemical physics. 1983;79(2):926–35. 10.1063/1.445869 [DOI] [Google Scholar]

[pone.0251910.ref040] 40.Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry. 1997;18(12):1463–72. [DOI] [Google Scholar]

[pone.0251910.ref041] 41.Darden T, York D, Pedersen L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of chemical physics. 1993;98(12):10089–92. 10.1063/1.464397 [DOI] [Google Scholar]

[pone.0251910.ref042] 42.Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. The Journal of chemical physics. 2007;126(1):014101. 10.1063/1.2408420 . [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref043] 43.Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of applied physics. 1981;52(12):7182–90. 10.1063/1.328693 [DOI] [Google Scholar]

[pone.0251910.ref044] 44.Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. Journal of Molecular Graphics. 1996;14(1):33–8. 10.1016/0263-7855(96)00018-5 [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref045] 45.Kraus D. Consolidated data analysis and presentation using an open-source add-in for the Microsoft Excel® spreadsheet software. Medical Writing. 2014;23(1):25–8. 10.1179/2047480613Z.000000000181 [DOI] [Google Scholar]

[pone.0251910.ref046] 46.Hunter JD. Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering. 2007;9(3):90–5. 10.1109/MCSE.2007.55 [DOI] [Google Scholar]

[pone.0251910.ref047] 47.Kumari R, Kumar R, Lynn A. g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations. Journal of Chemical Information and Modeling. 2014;54(7):1951–62. 10.1021/ci500020m [DOI] [PubMed] [Google Scholar]

[pone.0251910.ref048] 48.Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral research. 2015;115:21–38. Epub 12/29. 10.1016/j.antiviral.2014.12.015 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref049] 49.Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020. 10.1038/s41586-020-2601-5 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref050] 50.Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW, Bernardini JP, et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. The EMBO Journal. 2020;39(18):e106275. 10.15252/embj.2020106275 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0251910.ref051] 51.Bosken YK, Cholko T, Lou Y-C, Wu K-P, Chang C-eA. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease. Frontiers in Molecular Biosciences. 2020;7(174). 10.3389/fmolb.2020.00174 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

Farzin Sohraby

Hassan Aryapour

Roles

Abstract

Introduction

Method

Results & discussion

SuMD simulation of the unbinding pathways

Table 1. The duration times of the unbinding pathways of the inhibitors (ns) with respect to their activity.

Fig 1. Structure of SARS-Cov-2 Plpro enzyme.

Fig 2. The details of the unbinding pathway of GRL0617 in three series of replicas.

Fig 3. The details of the unbinding pathway of PLP_Snyder441 from SARS-CoV-2 Plpro in three series of replicas.

Fig 4. The details of the unbinding pathway of PLP_Snyder495 from SARS-CoV-2 Plpro in three series of replicas.

Fig 5. The details of the unbinding pathway of PLP_Snyder530 from SARS-CoV-2 Plpro in three series of replicas.

Fig 6. The flexibility of the BL2 loop.

Conclusion

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

Emilio Gallicchio

Roles

Author response to Decision Letter 0

Decision Letter 1

Emilio Gallicchio

Roles

Acceptance letter

Emilio Gallicchio

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation

Farzin Sohraby

Hassan Aryapour

Roles

Abstract

Introduction

Method

Results & discussion

SuMD simulation of the unbinding pathways

Table 1. The duration times of the unbinding pathways of the inhibitors (ns) with respect to their activity.

Fig 1. Structure of SARS-Cov-2 Plpro enzyme.

Fig 2. The details of the unbinding pathway of GRL0617 in three series of replicas.

Fig 3. The details of the unbinding pathway of PLP_Snyder441 from SARS-CoV-2 Plpro in three series of replicas.

Fig 4. The details of the unbinding pathway of PLP_Snyder495 from SARS-CoV-2 Plpro in three series of replicas.

Fig 5. The details of the unbinding pathway of PLP_Snyder530 from SARS-CoV-2 Plpro in three series of replicas.

Fig 6. The flexibility of the BL2 loop.

Conclusion

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

Emilio Gallicchio

Roles

Author response to Decision Letter 0

Decision Letter 1

Emilio Gallicchio

Roles

Acceptance letter

Emilio Gallicchio

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases